NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Recludix Pharma

Recludix Pharma

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://recludixpharma.com/

Last Round

Series B

Jan 12, 2026

Total Funding Raised

$248M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Recludix Pharma is a biotechnology company that develops innovative small-molecule inhibitors for challenging protein targets to treat cancer and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

small-molecule therapeuticsdrug discovery platformSHP2 inhibitorbiotechoncology therapeuticsinflammatory disease treatmentundruggable targetsDNA-encoded librariesDELstructure-based drug designbiopharmadrug discovery pipelinepreclinical developmentSTAT6 inhibitorpharma partnering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Recludix Pharma Comps

Public and private peers based on sector, stage, and business model.

Recludix Pharma comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Recludix Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 12, 2026
StrategicJul 20, 2023
Series ANov 15, 2021

Key People

Founding team and executive leadership

Brian Hodous

Co-Founder, Chief Scientific Officer

Founding Team

Nancy Whiting

Chief Executive Officer

Executive Team

Recludix Pharma Investors

Notable investors and investment history

Recludix Pharma investors
InvestorRounds
Access IndustriesSeries A
Westlake Village BioPartnersSeries A, Series B
New Enterprise Associates (NEA)Series A
Alexandria Venture InvestmentsSeries B
New Enterprise AssociatesSeries A, Series B
Access BiotechnologySeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 16, 2026

    Catherine Bovenizer promoted to Chief Financial Officer.

  • Mar 16, 2026

    Ajay Nirula, M.D., Ph.D. promoted to president and head of research and development.

Recludix Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Recludix Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Recludix Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range54
Year Founded2019
Last FundingJan 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.